1800 OWENS STREET, SAN FRANCISCO, CA
Board Expansion; Timothy Coughlin Appointed as Class III Director
Material disclosure
Provides Corporate Update and Reports First Quarter 2026 Financial Results
Annual Report to Security Holders
Executive Departure - Mark Eisner Steps Down as CMO of Vir Biotechnology
Marianne De Backer Appointed President of Vir Biotechnology, Inc.
Other Events
Vir Biotechnology Enters Underwriting Agreement for $141.1 Million Offering
Q1
FY 2024
Q3
Q2
FY 2023
Prospectus filed pursuant to Rule 424(b)(5)
Registration Statement for Securities to be Offered to Employees
S-3ASR
Additional Proxy Materials
Definitive Proxy Statement
Notice of Proposed Sale of Securities
Initial Statement of Beneficial Ownership
Statement of Changes in Beneficial Ownership
S-1MEF
Correspondence
Submission Upload